Cerdulatinib is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase II drugs for Cutaneous T-Cell Lymphoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cerdulatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cerdulatinib overview

Cerdulatinib (PRT-2070, PRT-062070, DMVT-502) is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, B-cell non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma and mantle cell lymphoma), arthritis, cutaneous T-cell lymphoma, Waldenstrom's macroglobulinemia, atopic dermatitis, vitiligo and inflammatory skin diseases, peripheral T-cell lymphoma including angioimmunoblastic T cell lymphoma, follicular T-cell lymphoma, nodal lymphomas of T follicular helper, anaplastic large cell lymphoma, hepatosplenic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, angioimmunoblastic T cell lymphoma and extranodal NK/T-cell lymphoma. The drug candidate is administered through oral, topical and ophthalmic routes. PRT-062070 is a dual SYK-JAK inhibitor. It blocks the B-cell receptor pathway via Syk and cytokine pathways via JAK 1, 3 and Tyk 2.

The drug candidate was also under development for the treatment of various ophthalmic indications and alopecia areata, anaplastic large cell lymphoma.

Alexion Pharmaceuticals overview

Alexion Pharmaceuticals (Alexion) discovers, develops, and markets therapies based on complement biology and inhibition for rare diseases. Deep understanding of rare disease enables the company to innovate and enter new areas, where there is a great unmet medical need. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody positive patients. The company also offers novel enzyme replacement therapies for patients with lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), and ultra-rare metabolic disorders. Alexion is headquartered in New Haven, Connecticut, the US.

For a complete picture of Cerdulatinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.